OMEROS CORP (OMER) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 94.96M USD | Liabilities, Current |
| Cash and equivalents | 1.99M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 11.71M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 842.00K USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $94.96M | $1.99M | (m) | $11.71M | $842.00K | (m) |
| 2026-03-31 | (m) | $59.44M | $1.91M | (m) | $6.75M | $183.00K | (m) |
| 2025-12-31 | (m) | $78.06M | $9.66M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $80.76M | $2.40M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $85.50M | $1.90M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $83.22M | $4.26M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $79.53M | $3.40M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $55.62M | $1.52M | $121.64M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $59.48M | $2.12M | $156.79M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $59.06M | $1.83M | $228.48M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $53.32M | $7.11M | $164.76M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $147.18M | $30.64M | $279.67M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $143.54M | $6.60M | $334.59M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $139.19M | $3.83M | $367.73M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $136.38M | $11.01M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $39.51M | $145.53M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $38.50M | $14.14M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $35.07M | $8.96M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $51.79M | $100.81M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $42.82M | $7.42M | (m) | (m) | $712.00K | (m) |
| 2021-06-30 | (m) | $47.70M | $12.70M | (m) | (m) | $978.00K | (m) |
| 2021-03-31 | (m) | $43.43M | $9.03M | (m) | (m) | $1.19M | (m) |
| 2020-12-31 | (m) | $36.74M | $10.50M | (m) | (m) | $1.35M | (m) |
| 2020-09-30 | (m) | $47.72M | $21.07M | (m) | (m) | $1.54M | (m) |
| 2020-06-30 | (m) | $38.05M | $1.96M | (m) | (m) | $1.89M | (m) |
| 2020-03-31 | (m) | $57.94M | $7.12M | (m) | (m) | $1.21M | (m) |
| 2019-12-31 | (m) | $55.46M | $3.08M | (m) | (m) | $1.15M | (m) |
| 2019-09-30 | (m) | $46.75M | $8.86M | (m) | (m) | $1.17M | (m) |
| 2019-06-30 | (m) | $40.67M | $3.99M | (m) | (m) | $1.19M | (m) |
| 2019-03-31 | (m) | $44.51M | $4.05M | (m) | (m) | $736.00K | (m) |
| 2018-12-31 | (m) | $37.36M | $5.86M | (m) | (m) | $88.00K | (m) |
| 2018-09-30 | (m) | $24.59M | $2.79M | (m) | (m) | $214.00K | (m) |
| 2018-06-30 | (m) | $24.44M | $2.88M | (m) | (m) | $235.00K | (m) |
| 2018-03-31 | (m) | $24.63M | $1.19M | (m) | (m) | $247.00K | (m) |
| 2017-12-31 | (m) | $26.31M | $3.39M | (m) | (m) | $443.00K | (m) |
| 2017-09-30 | (m) | $24.69M | $1.03M | (m) | (m) | $822.00K | (m) |
| 2017-06-30 | (m) | $24.75M | $3.39M | (m) | (m) | $905.00K | (m) |
| 2017-03-31 | (m) | $16.97M | $1.28M | (m) | (m) | $960.00K | (m) |
| 2016-12-31 | (m) | $16.07M | $2.22M | (m) | (m) | $1.13M | (m) |
| 2016-09-30 | (m) | $16.06M | $10.30M | (m) | (m) | $1.40M | (m) |
| 2016-06-30 | (m) | $16.07M | $4.59M | (m) | (m) | $1.78M | (m) |
| 2016-03-31 | (m) | $17.52M | $978.00K | (m) | (m) | $1.97M | (m) |
| 2015-12-31 | (m) | $16.25M | $1.36M | (m) | (m) | $472.00K | (m) |
| 2015-09-30 | (m) | $22.27M | $601.00K | (m) | (m) | $445.00K | (m) |
| 2015-06-30 | (m) | $20.10M | $2.56M | (m) | (m) | $633.00K | (m) |
| 2015-03-31 | (m) | $20.07M | $1.44M | (m) | (m) | $566.00K | (m) |
| 2014-12-31 | (m) | $18.43M | $354.00K | (m) | (m) | $568.00K | (m) |
| 2014-09-30 | (m) | $14.40M | $750.00K | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $12.17M | $1.53M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $10.23M | $567.00K | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $11.87M | $1.38M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $11.90M | $1.15M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $10.90M | $1.72M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $10.59M | $1.28M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $9.32M | $1.52M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $21.81M | $1.06M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $17.25M | $7.27M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $18.74M | $16.80M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $18.98M | $4.00M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $15.81M | $4.89M | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $14.34M | $4.16M | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | $3.92M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $15.37M | $3.28M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $2.80M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $2.87M | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $820.00K | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | $12.73M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |